The HALO Study: A Phase I-II of the Oral HSP90 Inhibitor Debio 0932 in combination with SOC in First- and Second-line Therapy of Advanced NSCLC

Presented at ASCO 2014, Chicago, USA

J Corral (1), L Paz-Ares (1), M Provencio (2), J Bennouna (3), S Ponce-Aix (4), R Plummer (5), J-P Delord (6), N Isambert (7), JM Trigo (8), R Belli (9), S Brienza (9), C Zanna (9), D Purcea (9), V Calvo (2), M Alonso (1), H Sellenart (3), S Hiret (3), A Martinez Marti (10), E Felip (10)

  1. University Hospital, Seville, Spain
  2. Hopital Universitario, Madrid, Spain
  3. Institut de Cancerologie, Nantes, France
  4. Hospital 12 de Octubre, Madrid, Spain
    Newcastle University, Newcastle, UK
  5. Institut Claudius Regaud, Toulouse, France
  6. Centre Georges François Leclerc, Dijon, France
  7. Hospital Universitario, Malaga, Spain
  8. Debiopharm International SA, Lausanne, Switzerland
  9. University Hospital, Barcelona, Spain